Advancing Precision Care in HR+/HER2- Metastatic Breast Cancer: ESR1 Testing and the Expanding Role of Oral SERDs

Name: Advancing Precision Care in HR+/HER2- Metastatic Breast Cancer: ESR1 Testing and the Expanding Role of Oral SERDs
Start: 2026-09-27T10:50:00-04:00
End: 2026-09-27T11:35:00-04:00
Location: New York, NY

General Session

Advancing Precision Care in HR+/HER2- Metastatic Breast Cancer: ESR1 Testing and the Expanding Role of Oral SERDs

45 min

Sunday, September 27, 2026

10:50 AM - 11:35 AM

Supported by educational grants from AstraZeneca and Stemline Therapeutics Inc, a Menarini Company.

Presenter
- Sara Nunnery MD, MSCI

Breast Cancers